Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) had its price target decreased by analysts at HC Wainwright from $25.00 to $15.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's target price would suggest a potential upside of 426.32% from the company's previous close.

Several other equities research analysts have also recently commented on the company. Wedbush raised Sangamo Therapeutics from a "neutral" rating to an "outperform" rating and set a $16.00 target price for the company in a research note on Monday, February 27th. Wells Fargo & Company decreased their target price on Sangamo Therapeutics from $20.00 to $15.00 and set an "overweight" rating for the company in a research note on Wednesday, January 4th. Royal Bank of Canada decreased their target price on Sangamo Therapeutics from $22.00 to $13.00 and set an "outperform" rating for the company in a research note on Thursday, February 23rd. Finally, Bank of America cut Sangamo Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $8.00 to $5.00 in a research note on Friday, January 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $13.83.

Sangamo Therapeutics Stock Performance

NASDAQ:SGMO opened at $2.85 on Friday. Sangamo Therapeutics has a 52 week low of $2.63 and a 52 week high of $6.42. The firm's fifty day moving average is $3.22 and its 200-day moving average is $4.03. The firm has a market cap of $480.17 million, a P/E ratio of -2.28 and a beta of 1.17.

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. Sangamo Therapeutics had a negative net margin of 172.76% and a negative return on equity of 61.19%. The business had revenue of $27.23 million for the quarter, compared to analysts' expectations of $26.86 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The business's quarterly revenue was down 2.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sangamo Therapeutics will post -1.31 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently bought and sold shares of the stock. Signaturefd LLC raised its holdings in shares of Sangamo Therapeutics by 617.1% in the fourth quarter. Signaturefd LLC now owns 11,774 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 10,132 shares during the last quarter. Quadrant Capital Group LLC increased its stake in Sangamo Therapeutics by 848.9% in the 4th quarter. Quadrant Capital Group LLC now owns 12,734 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 11,392 shares during the last quarter. Handelsbanken Fonder AB bought a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $48,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Sangamo Therapeutics by 31.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,205 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 2,445 shares during the last quarter. Finally, New Harbor Financial Group LLC bought a new position in shares of Sangamo Therapeutics in the third quarter valued at approximately $51,000. 59.34% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

(Get Rating)

Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.

Further Reading

• Get a free copy of the StockNews.com research report on Sangamo Therapeutics (SGMO)
• MarketBeat Week in Review – 2/27 – 3/3
• The 3 Most Upgraded Stocks Are Reversing
• How to Find Blue Chip Dividend Stocks
• Zscaler, Inc Plummets, Is It Time To Buy The Dip?
• What is a Good Dividend Yield? How to Decide

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.